Tesamorelin and sermorelin are both GHRH analogs. Same receptor, same axis, same basic mechanism. The comparison people actually want is narrower than the one they usually search for: these two are not different classes of compound, they are two different structural answers to the same engineering problem.
That problem is stability. Native growth hormone releasing hormone is cleared from plasma in minutes. Sermorelin solves for potency by keeping only the part of the molecule that does the work. Tesamorelin solves for durability by keeping the whole molecule and armoring the part that gets cut. Everything that separates the two follows from that choice.
There is also a regulatory difference worth stating up front, because it is the single most consequential fact in this comparison and most write-ups skip it. It is covered below.
All compounds referenced here are supplied for laboratory and research use only. They are not for human consumption. Nothing in this post is dosing, administration, or safety guidance.
The short version
| Sermorelin | Tesamorelin | |
|---|---|---|
| Classe | GHRH analog | GHRH analog |
| Sequence | GRF(1-29) amide, 29 amino acids | Full-length GHRH(1-44) |
| Structural modification | C-terminal amidation of a truncated fragment | Trans-3-hexenoic acid attached at the N-terminal tyrosine |
| Receptor target | GHRH receptor (GHRHR) | GHRH receptor (GHRHR) |
| Design goal | Shortest fragment retaining full GHRH activity | Resistance to enzymatic degradation |
| Reported plasma stability | Short, cleared in minutes | Longer than unmodified GHRH fragments |
| Pharmaceutical form | Geref, discontinued in the US in 2008 | Egrifta, FDA approved 2010; successor formulations still marketed |
| Research vial sizes at WWP | 5 mg | 5mg, 10mg |
Sermorelin: the shortest fragment that still works
Human GHRH is 44 amino acids long. Structure-activity work in the early 1980s established that biological activity at the GHRH receptor sits almost entirely in the first 29 residues, and that the truncated fragment retains the full potency of the parent hormone. Sermorelin is that fragment, synthesized and amidated at the C-terminus: GRF(1-29) amide.
The receptor is GHRHR, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding activates Gs, raises cAMP, and drives growth hormone synthesis and release from cells that were going to produce it anyway. The somatostatin brake and the IGF-1 feedback loop stay intact, which is why GHRH analogs are used as tools for studying axis regulation rather than as a way of bypassing it.
The limitation is at the N-terminus. Dipeptidyl peptidase-4 cleaves the first two residues off GHRH and its fragments, and the resulting GHRH(3-44) or GHRH(3-29) has essentially no activity at the receptor. Sermorelin inherits that vulnerability unmodified, and published pharmacokinetic work reports a plasma half-life measured in minutes.
Sermorelin acetate was marketed in the United States as Geref for pituitary function testing and pediatric endocrinology. The marketing authorization holder withdrew it from the US market in 2008. That was a commercial and supply decision, not a regulatory action against the molecule, and it is why sermorelin is now encountered almost exclusively as a research compound and reference standard.
Tesamorelin: the full-length molecule, armored
Tesamorelin takes the opposite approach. It keeps all 44 residues of human GHRH and attaches a trans-3-hexenoic acid group to the N-terminal tyrosine.
That modification is aimed at exactly the site sermorelin leaves exposed. Occupying the N-terminus interferes with dipeptidyl peptidase-4 access to the cleavage point, and published pharmacokinetic work reports a longer plasma half-life for tesamorelin than for unmodified GHRH or its short fragments. Receptor pharmacology is unchanged: tesamorelin binds and activates the same GHRHR, through the same Gs and cAMP pathway, on the same cells.
So the difference between the two is not what they do. It is how long they persist while doing it.
The regulatory fact, stated plainly
Tesamorelin has an approved pharmaceutical form. The FDA approved it in 2010 under the brand name Egrifta, indicated for the reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy. That approval is real, narrow, and specific to that product and that indication.
The material sold as a research compound is not that pharmaceutical product. It carries no approval, no indication, and no human-use authorization of any kind. It is supplied for laboratory and research use only. Those two things share a molecule and nothing else, and conflating them is the most common error in write-ups on this compound.
Sermorelin sits differently. Its pharmaceutical form was discontinued, so there is no currently marketed approved product in the US at all. The research compound is likewise research use only.
Structure and mechanism comparison
| Property | Sermorelin | Tesamorelin |
|---|---|---|
| Residue count | 29 | 44 |
| Relationship to native GHRH | Truncated fragment, sequence unmodified | Full sequence, chemically modified at N-terminus |
| Modifica | C-terminal amide | Trans-3-hexenoic acid on N-terminal Tyr, C-terminal amide |
| Receptor | GHRHR | GHRHR |
| G protein coupling | Gs | Gs |
| Second messenger | cAMP, PKA | cAMP, PKA |
| DPP-4 cleavage site | Exposed | Sterically hindered by the hexenoyl group |
| Reported plasma half-life | Minutes | Longer than unmodified GHRH fragments |
| Endogenous feedback preserved | Yes | Yes |
| Synthesis complexity | Moderate, 29 residues | Higher, 44 residues plus an acylation step |
That last row is the one resellers feel. A 44-residue peptide requires more synthesis cycles than a 29-residue one, carries a larger population of possible deletion sequences, and adds a chemical modification step that has to be driven to completion and then purified. That is the reason tesamorelin carries a materially higher per-vial cost than sermorelin at the same milligram strength, and the reason the purity spec on the certificate of analysis deserves more attention on the longer molecule.
What each is examined for
Neither compound has an approved human indication in the research-compound form sold here. The following describes published research contexts, not outcomes or claims.
Sermorelin appears in published research examining:
- GHRH receptor structure-activity relationships across fragment lengths
- Pituitary somatotroph responsiveness as an index of pituitary function
- Hypothalamic-pituitary axis feedback regulation in an intact endogenous release model
- Age-related changes in growth hormone axis output in animal models
- Comparative pharmacology as the unmodified reference against engineered GHRH analogs
Tesamorelin appears in published research examining:
- Visceral adipose tissue endpoints, the line of investigation that produced the approved indication
- Hepatic fat content, including the JAMA-published work on liver fat in HIV-associated lipodystrophy
- Growth hormone axis output over extended timeframes, where fragment half-life is limiting
- Cognitive endpoints, including a randomized placebo-controlled trial in older adults that reported executive-function effects, an independent research line
- Structure-stability relationships in acylated peptide design
Why “tesamorelin ipamorelin” is a search people run
A meaningful share of tesamorelin search traffic is for the pairing with ipamorelin rather than for the compound alone. The reason is the same logic that produced the CJC-1295 and ipamorelin combination.
Tesamorelin is a GHRH analog acting at GHRHR. Ipamorelin is a ghrelin receptor agonist acting at GHS-R1a. Two receptors, two signalling pathways, one target cell population. Published studies combining a GHRH analog with a ghrelin receptor agonist report a larger growth hormone response than either class produced alone in the same model. The two inputs are not redundant - one drives the somatotroph directly through cAMP, the other works through the ghrelin receptor system - though the mechanism behind the outsized combined response has never been fully resolved in the literature.
We covered that pairing logic in full in sermorelin vs ipamorelin, which is the better starting point if the cross-class comparison is what you are actually after.
Common questions
Is tesamorelin similar to Ozempic?
No, and the two are not related mechanistically. Semaglutide, the compound in Ozempic, is a GLP-1 receptor agonist. It binds the glucagon-like peptide-1 receptor, a receptor expressed in the pancreas, gut, and central nervous system, and its documented pharmacology runs through insulin secretion and gastric emptying. Tesamorelin is a GHRH analog. It binds the GHRH receptor on pituitary somatotrophs and its pharmacology runs through growth hormone release. Different receptors, different tissues, different signalling, different research literature. The only thing the two share is that both are peptides and both have approved pharmaceutical forms for unrelated indications.
Are tesamorelin and sermorelin the same thing?
No. They are the same class acting at the same receptor, but they are structurally distinct molecules. Sermorelin is a 29-residue truncation of native GHRH with no chemical modification. Tesamorelin is the full 44-residue sequence carrying a trans-3-hexenoic acid group at the N-terminus. The modification is what separates their stability profiles.
Which one is more stable?
Tesamorelin, by design. The hexenoyl group at the N-terminal tyrosine hinders dipeptidyl peptidase-4 access to the cleavage site that clears unmodified GHRH and its fragments within minutes. Published pharmacokinetic work reports a longer plasma half-life for tesamorelin than for unmodified GHRH fragments. Sermorelin has no such protection, which is precisely why it serves as the unmodified comparator in stability studies.
Is tesamorelin FDA approved?
The pharmaceutical product Egrifta was approved by the FDA in 2010 for the reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy. That approval applies to that product for that indication. Research-grade tesamorelin is a different article entirely: it carries no approval, no indication, and is supplied for laboratory and research use only, not for human consumption.
Why was sermorelin’s pharmaceutical form discontinued?
Geref’s marketing was discontinued in 2008 by the authorization holder, with FDA formally withdrawing the approval in 2009. It was a commercial and supply decision rather than a regulatory action against the compound. Sermorelin remained in use as a research reference standard, which is the form it is supplied as today.
Do tesamorelin and sermorelin bind the same receptor?
Yes. Both are agonists at GHRHR, the class B GPCR on anterior pituitary somatotrophs, and both signal through Gs and cAMP. Their differences are in sequence length, chemical modification, and the resulting stability profile, not in receptor target.
Where to source these compounds
We manufacture both and ship direct in 10-vial packs. No retail packaging, no relabeling step, which is why the vials arrive unlabeled and why the per-vial cost lands where it does.
- Tesamorelin, 5mg and 10mg
- Sermorelin, 5mg
- Ipamorelin, 5mg and 10mg
Storage is standard cold chain for lyophilized peptides. Solvent compatibility and handling parameters are documented in the published peptide chemistry literature and are the researcher’s call.
Every batch we ship has a certificate of analysis, and the COA library is open without an account. Every batch is ≥99% purity. Send us a COA from any independent test and we’ll issue store credit regardless of what it shows.
All products are supplied for laboratory and research use only. Not for human consumption, ingestion, injection, or therapeutic use.